Sedana Medical publishes prospectus and certain new financial information in connection with the listing change to Nasdaq Stockholm

Sedana Medical AB (publ) (the "Company" or "Sedana Medical") announced on 19 January 2023 that Nasdaq Stockholm's listing committee had approved the Company's application for admission to trading of the Company's shares on Nasdaq Stockholm. The Company has prepared a prospectus in connection with the listing change, which today has been approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) (the "Prospectus"). The Prospectus (only in Swedish) is available on the Company's website.

Publication of the Prospectus

For complete information about the listing change, reference is made to the Prospectus that has been prepared by the Company and made available on the Company's website (www.sedanamedical.se).

The Prospectus has been prepared as a simplified prospectus in accordance with Article 14 of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended (the "Prospectus Regulation"). The Swedish Financial Supervisory Authority (the ''SFSA''), as the Swedish national competent authority, has approved the Prospectus in accordance with Article 20 of the Prospectus Regulation. The SFSA only approves the Prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. The approval should not be considered as an endorsement of the Company or of the securities described in the Prospectus. The SFSA does not guarantee the accuracy or completeness of the factual information contained in the Prospectus. Each investor is advised to make its own assessment of whether it is appropriate to invest in the Company's shares.

The listing change is not combined with any offer of shares. The Company's shares will continue to trade under the ticker SEDANA and ISIN code SE0015988373. The Company's shareholders are not required to take any actions due to the listing change.

Timetable

First day of trading on Nasdaq Stockholm is scheduled for 25 January 2023 and last day of trading on Nasdaq First North Growth Market is scheduled for 24 January 2023.

New financial information

The prospectus contains certain financial information regarding Sedana Medical's capitalization and net indebtedness as of 31 October 2022 that has not previously been published. The new financial information is presented in the tables below. The information has not been reviewed by the Company's auditor.

Capitalization (KSEK)

Net indebtedness (KSEK)

Advisers

Pareto Securities AB and Advokatfirman Lindahl KB are Sedana Medical’s financial and legal advisers respectively, in connection with the listing change.

For additional information, please contact:
Johannes Doll, CEO, +46 76 303 66 66
Johan Spetz, CFO, +46 730 36 37 89
ir@sedanamedical.com

Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.

About Sedana Medical

Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordic, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq First North Growth Market (SEDANA) and headquartered in Stockholm, Sweden.